Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 12/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 12/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 12/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25678733 | 0.83 | CSNK2A2 (0.47) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1A1 | |
| SCHEMBL30434685 | 0.83 | CDK2 (0.35) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CCNT1 | |
| SCHEMBL25678728 | 0.83 | CSNK2A2 (0.46) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1A1 | |
| SCHEMBL30434406 | 0.83 | CSNK2A2 (0.46) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1A1 | |
| SCHEMBL27129188 | 0.81 | PIK3CA (0.48) | CSNK2A2CSNK2BCSNK2A1CYSLTR1 | |
| SCHEMBL27008414 | 0.81 | PIK3CA (0.48) | CSNK2A2CSNK2BCSNK2A1CYSLTR1 | |
| SCHEMBL30434590 | 0.81 | CSNK2A2 (0.45) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1A1 | |
| SCHEMBL27132843 | 0.81 | CSNK2A2 (0.45) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1A1 | |
| SCHEMBL30434488 | 0.81 | CSNK2A2 (0.45) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1A1 | |
| SCHEMBL26884970 | 0.81 | CSNK2A2 (0.45) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| EP-4444714-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CSNK2A2 366/4885CSNK2B 313/4885CSNK2A1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.